The influence of the drug pair of Baizhu-Fuzi on the survival time of nude mice which have bone metastasis of breast cancer and the TGF-β1 and PTHrP in their serum
10.3969/j.issn.1001-1528.2018.03.007
- VernacularTitle:附子-白术药对对乳腺癌骨转移裸鼠生存时间及血清中TGF-β1、PTHrP的影响
- Author:
Xu-Feng CHENG
1
;
Xin-Feng ZHANG
;
Qi LIU
;
Cui-Xia QIAO
;
Hui-Duo ZHAO
;
Bei-Bei WANG
Author Information
1. 河南中医药大学第一附属医院
- Keywords:
the drug pair of Baizhu-Fuzi;
bone metastasis of breast cancer;
survival time;
TGF-β;
PHTrP
- From:
Chinese Traditional Patent Medicine
2018;40(3):544-548
- CountryChina
- Language:Chinese
-
Abstract:
AIM To observe the drug pair Baizhu-Fuzi's protection on the breast cancer nude mice with bony metastasis and to explore the mechanism of bone metastasis.METHODS Nude mouse models of breast cancer with bone metastasis were developed through injection of breast cancer cell MDA-MB-231BO into the left ventricle.Nude mice were randomly divided into group A and group B.Group A were subdivided into model group,zoledronic acid group and the drug pair of Baizhu-Fuzi group;and Group B were subdivided into sham-operation group,model group,zoledronic acid group and Baizhu-Fuzi group were subsequently administered with the intervention accordingly.The nude mice in group A had their surviving time and the weight changes observed;and those in group B had the degree of bone metastasis examined.Tartrate resistant acid phosphatase (TRAP) method for quantitative determination of osteoclast in bone metastasis,and ELISA method were employed to check the content of TGF-β1 and PTHrP in serum.RESULTS Compared to the model group,Baizhu-Fuzi group displayed distinctly longer survival time (P ＜ 0.05),reduced rate of weight loss 6 weeks after modeling (P ＜ 0.05),significantly declined degree of bone metastasis (P ＜ 0.01),and significantly decreased quantity of TRAP (+) cell (P ＜ 0.05) and serum TGF-β1 and PTHrP (P ＜ 0.05).CONCLUSION The drug pair,Baizhu-Fuzi's influence in TGFβ signal path control and PTHrP expression reduction may contribute to the weight loss management,prolonged survival time,osteolytic bone defect rectification in mouse models of breast cancer with bone metastasis.
